As COVID-19 vaccinations continue, it’s a good time to ask: How much do the drug companies responsible for the vaccines stand to make?
A rundown from Fox Business and CNN reporting.
Pfizer and BioNTech
Pfizer and BioNTech vaccine was first on the market, receiving its EUA in December. It’s a two-shot vaccine found to be 95% effective.
The CDC reported this vaccine to account for 46.8 million doses in the U.S. at this point.
The profit expected by both companies combined is $15 billion. That’s on top of Pfizer’s estimated $975 million in 2020 vaccine revenue.
Pfizer and BioNTech plan to supply up to 1.3 billion doses of the vaccine worldwide by the end of 2021.
Approved for emergency use by the FDA after it was found to be 94.5% effective, the Moderna vaccine accounts for more than 44.9 million of the total vaccine doses administered in the U.S., according to the CDC.
Moderna’s fourth-quarter earnings report revealed an expectation of $18.4 billion in anticipated product sales related to its vaccine.
The company generated just $60 million – with an “M” — in sales in 2019 and has never previously licensed a product.
Moderna’s Moderna is on track to produce and deliver the first 100 million doses by the end of March.
Johnson & Johnson
The company’s vaccine, the only one to need only a single shot, was given an EUA Feb. 27 and CDC approval the next day.
According to a Fox Business story, the company plans to deliver 3.9 million vaccine doses, with enough single-shot vaccines by the end of this month to vaccinate more than 20 million Americans. The expectation is for 100 million single-shot vaccines by June.
The expected delivery of 1 billion doses by the end this year means up to $10 billion in revenues.